Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight | NCT07770841 | Trialant

RecruitingInterventionalPhase 3Updated Aug 18, 2026

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

Efficacy and Safety of Once Daily Oral Semaglutide in Adults With Overweight or Obesity

Overview

Key facts that identify this study and show where it stands today.

What the study is about and why it is being run, in the researchers' own words.

Official Title: Efficacy and Safety of Once Daily Oral Semaglutide in Adults With Overweight or Obesity
Brief Summary: The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semaglutide that can be used for treating participants living with overweight or obesity.

The medical conditions and diseases this study investigates.

The treatments and procedures being evaluated in this study.

Who can join this study and the criteria used to decide.

Ages Eligible for Study: Adult (18-64)Older Adult (65+)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Eligibility Criteria: Inclusion Criteria:

Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.

Female or male (sex at birth).

Age 18 years or above at the time of signing the informed consent.

Body mass index (BMI) of

≥ 27.0 kilogram per square meter (kg/m^2) with the presence of at least one weight-related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or CV disease.

OR

≥ 30.0 kg/m^2.

History of at least one self-reported unsuccessful dietary effort to lose body weight.

Exclusion Criteria:

A self-reported change in body weight greater than (>) 5% within 90 days before screening irrespective of medical records.

HbA1c ≥ 6.5% (48 millimoles per mole [mmol/mol]) as measured by the central laboratory at screening.

Consistent use of glucagon like peptide-1 (GLP-1) receptor agonists, including medication with glucagon like peptide-1 receptor agonist (GLP-1 RA) activity like dual GLP-1/gastric inhibitory peptide RAs, or amylin analogues before screening. Consistent use is defined as treatment.

How the study is designed and how its participant groups are organized.

The people to reach with questions about this study or how to join it.

Novo NordiskContact

clinicaltrials@novonordisk.com(+1) 866-867-7178

Where the study is run and whether each site is currently recruiting.

Uni of Alabama at BirminghamNot yet recruiting

Birmingham, Alabama 35296, United States

The organizations and people involved in this study.

Other registered studies that closely resemble this one.